Delivery Order SPE2DR25D3005-SPE2DR26FP8LD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,702.11 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal insert (8-count packages) on December 22, 2025, with a completion date of December 23, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a $6,425.86 delivery order to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (8-count package) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract reflects a routine pharmaceutical supply procurement from the company's existing indefinite delivery contract with DLA. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,244.00 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (8-count package) on November 20, 2025, with an ultimate completion date of November 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,352.04 to AmerisourceBergen Drug Corp for the supply of Yuvafem 10 mcg vaginal inserts (18 count) on January 6, 2026, with an ultimate completion date of January 7, 2026. This firm fixed-price, competitively awarded delivery order was fulfilled from the place of performance in Conshohocken, Pennsylvania. The award represents a task order against AmerisourceBergen's parent company, Cencora, Inc.'s, substantial Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Yuvafem 10 micrograms vaginal inserts (8-count packages) on September 4, 2025, with a ceiling value of $1,565.46. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. This delivery...
- The Defense Logistics Agency awarded a $2,103.45 delivery order to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18-count) on December 19, 2025, with an ultimate completion date of December 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 2, 2026, for the supply of Yuvafem 10 MCG vaginal insert (18-count) under a firm fixed-price contract with a ceiling value of $1,240.42. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of January 5, 2026. The place of performance is the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,937.84 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18-count) on September 29, 2025, with completion targeted for September 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18 units) under a firm fixed-price contract valued at $2,504.60. This award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside, competitively awarded delivery order, reflecting the contractor's proven capability...
- The Defense Logistics Agency awarded a delivery order valued at $7,675.32 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18-count) on September 9, 2025, with completion targeted for September 10, 2025. This competitive, non-set-aside award reflects a firm fixed-price arrangement and represents a direct order fulfillment under AmerisourceBergen's existing contract vehicle with the agency. The product will be performed from the contractor's location in Conshohocken,...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP8LDDelivery Order
On January 7, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $3,178.29 to AmerSourceBergen Drug Corp for Yuvafem 10 micrograms vaginal insert (8-pack). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 8, 2026, and will be performed at the awardee's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. The delivery order is issued under AmerSourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical supply agreement running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs worldwide. AmerSourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is a subsidiary of Cencora, Inc. (doing business as AmerSourceBergen). The parent company holds a separate $999,999,999.00 IDC with the DLA extending through December 2031, demonstrating the organization's significant role in supplying prescription medications, medical devices, and healthcare commodities across multiple therapeutic domains to military treatment facilities, veteran healthcare programs, and other federal medical institutions. The award of Yuvafem, a hormone replacement therapy medication, reflects the breadth of pharmaceutical products distributed through DLA's procurement channels to support Defense Health Agency operations and broader federal healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 1/6/26 |